Risk factors and predictors of psoriatic arthritis in patients with psoriasis

Azevedo, Valderílio Feijó; Buiar, Pedro Grachinski

doi:10.1590/s0365-05962013000200008

Cited by 11 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…V. Azevedo и соавт. [16] так-же показали взаимосвязь между раз-витием псориаза ногтей и ПсА, в особенности в сочетании с наслед-ственным фактором.…”

Section: Discussionunclassified

Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis

2014

View full text Add to dashboard Cite

Objectives(1) To investigate the demographic and clinical characteristics contributing to the delay from symptom onset to the first visit to a rheumatologist; (2) to compare clinical, radiographic and patient-reported outcome measures of those who saw a rheumatologist early in their disease course with those who were diagnosed later.MethodsAll psoriatic arthritis (PsA) patients, fulfilling CASPAR criteria, with an average disease duration of >10 years were invited for detailed clinical evaluation. The total lag time from symptom onset to their first rheumatological encounter was studied. The data were extracted from the referral letters and medical records. Patients were classified as early consulters or late consulters depending on whether they were seen by a rheumatologist within or beyond 6 months of symptom onset.Results283 PsA patients were studied. Median lag time from the disease onset to the first rheumatological assessment of the cohort was 1.00 years (IQR 0.5–2). 30% (n=86), 53% (n=149) and 71% (n=202) of the cohort were seen by a rheumatologist within 6 months, 1 and 2 years of symptom onset, respectively. PsA patients with low education status (OR 2.09, p=0.02) and Body Mass Index (OR 0.92, p=0.01) were significantly more likely to have a diagnostic delay of >2 years. On multiple stepwise regression analysis, the model predicted significant association of late consulters with the development of peripheral joint erosions (OR 4.25, p=0.001) and worse Health Assessment Questionnaire scores (OR 2.2, p=0.004).ConclusionsEven a 6-month delay from symptom onset to the first visit with a rheumatologist contributes to the development of peripheral joint erosions and worse long-term physical function.

show abstract

Section: Discussionunclassified

Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis

2014

View full text Add to dashboard Cite

show abstract

“…The hospital’s Center for Skin and Related Musculoskeletal Diseases (SARM), a specialist clinic treating patients with concomitant systemic rheumatic and skin diseases [ 10 ], has an extensive referral network within the catchment area making the patient population representative of a Northeastern metropolitan population. Patients that might qualify for the registry are identified by systematically screening the electronic medical record (EMR) system of the hospital using an algorithm previously found to be highly predictive of psoriasis [ 11 , 12 ]. Since the identified potentially eligible subjects will all have their diagnoses confirmed before entering the registry, we simplified the search algorithm to include patients with at least three diagnoses of PsO (ICD-9-CM code 696.1 or ICD-10 code L40.0) or at least three diagnoses of PsA (ICD-9-CM code 696.0 or ICD-10 code L40.5) who also have had a visit to the hospital from 2013 through 2014 for either diagnosis [ 13 , 14 ].…”

Section: Methodsmentioning

confidence: 99%

Rationale and Design of the Brigham Cohort for psoriasis and psoriatic arthritis registry (COPPAR)

et al. 2017

View full text Add to dashboard Cite

BackgroundPsoriasis (PsO) and psoriatic arthritis (PsA) are related conditions with poorly defined transition among them, risk factors for progression, complex treatment algorithms, and biomarkers for treatment response and long-term outcomes. We describe the development of a PsO/PsA registry at an academic medical center.MethodsWe developed a single-center PsO/PsA longitudinal disease registry including biorepository that captures relevant disease markers and treatment choices in a circumscribed population with a defined catchment area. We searched the electronic medical record for patients with visits in the last year for PsO or PsA. They formed the potentially eligible registry population. Baseline patient and provider questionnaires were developed using standardized measures, including demographics, comorbidities, medications, specific disease characteristics, functional status, quality of life, mental health, and resource use. An abbreviated set of items was collected every six month and at visits with treatment changes or disease flares. Biospecimens included blood (serum, plasma, DNA, RNA) and skin biopsy samples, with repeat collections of serum and plasma. Data from the EMR to augment the registry questionnaires are available on all patients.DiscussionSearching the Brigham EMR system from 2013 through 2014, we found 1694 patients with PsO and 1028 with PsA. Their mean age was 55 years and 53% were female. Of these 17% had diabetes, 38% hyperlipidemia, and 45% hypertension. The median BMI was 29.6. PsA patients used more systemic prednisone, MTX, and TNF alpha inhibitors (47%, 60%, and 66%) compared to PsO patients (28%, 20% and 21%). We have collected plasma in 410 patients, DNA/RNA in 453 patients. In conclusion, we have developed a PsO/PsA registry to better define longitudinal disease characteristics, perform biomarker studies, and examine treatment trends.

show abstract

“…Данные о факторах риска развития ПсА у боль-ных ПС противоречивы [34,35]. Есть данные, что развитию ПсА у больных ПС способствуют эндоген-ные и экзогенные факторы [34].…”

unclassified

“…Есть данные, что развитию ПсА у больных ПС способствуют эндоген-ные и экзогенные факторы [34]. К эндогенным фак- Факторами риска развития ПсА могут быть ко-морбидные состояния, ассоциированные с ПС.…”

unclassified